Clinical Trial Update: An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. [Phase 4]

View source ↗

Summary

Open-label, single-arm Phase 4 trial assessing prophylaxis for datopotamab deruxtecan–related stomatitis in patients with metastatic or inoperable locally recur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (Dato-DXd) (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Stomatitis | Phase 4 | Status: NOT_YET_RECRUITING